Scalper1 News
The U.S. Patent and Trademark Office ruled Wednesday against a patent challenge to Biogen’s (BIIB) blockbuster drug Tecfidera, holding out hope for denial of similar challenges against other drugs by hedge fund manager Kyle Bass. Biogen stock rose. The USPTO declined to hold a trial in response to Bass’s request for inter partes review (IPR) on Tecfidera’s patent with a number ending in 514, which expires in 2028. The office cited a “failure to Scalper1 News
Scalper1 News